Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 10

Results For "ICAR"

150 News Found

Shilpa Biologicals appoints Dr. Sridevi Khambhampaty as CEO
People | September 20, 2024

Shilpa Biologicals appoints Dr. Sridevi Khambhampaty as CEO

She brings an overall Techno Commercial experience of 22+ Years in various Organizations


Akums appoints Amrut Medhekar as CEO - CDMO Business
People | August 26, 2024

Akums appoints Amrut Medhekar as CEO - CDMO Business

e brings over 27+ years of rich pharmaceutical experience


Health Minister Nadda inaugurates ‘First Policy Makers’ Forum’ in New Delhi
News | August 20, 2024

Health Minister Nadda inaugurates ‘First Policy Makers’ Forum’ in New Delhi

These digital initiatives are expected to enhance the accessibility and efficiency of drug safety monitoring and standards compliance


Shilpa Pharma Lifesciences received CEP from EDQM for ursodeoxycholic acid
Drug Approval | August 01, 2024

Shilpa Pharma Lifesciences received CEP from EDQM for ursodeoxycholic acid

Ursodeoxycholic acid or ursodiol is a naturally occurring bile acid that is used dissolve cholesterol gall stones


Shilpa Pharma Lifesciences’ Unit 2 Raichur has cleared the ANVISA-Brazil GMP inspection
News | July 10, 2024

Shilpa Pharma Lifesciences’ Unit 2 Raichur has cleared the ANVISA-Brazil GMP inspection

The Unit has been issued GMP Certification from ANVISA-Brazil


Increasing public awareness on World Zoonoses Day
News | July 08, 2024

Increasing public awareness on World Zoonoses Day

India boasts the largest livestock population, with 536 million livestock and 851 million poultry


Shilpa Biologicals files Type IV DMF of recombinant Human Albumin 20% with USFDA
Drug Approval | June 06, 2024

Shilpa Biologicals files Type IV DMF of recombinant Human Albumin 20% with USFDA

This novel recombinant has been developed and is a patented novel recombinant Human Albumin 20% process


Biocon posts Q4 FY24 PAT at Rs. 135 Cr
News | May 17, 2024

Biocon posts Q4 FY24 PAT at Rs. 135 Cr

EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%


Kwality Pharmaceuticals receives approval from INVIMA for Ampoule and Vial product lines
Drug Approval | April 23, 2024

Kwality Pharmaceuticals receives approval from INVIMA for Ampoule and Vial product lines

Approval from Colombia's INVIMA will accelerate growth in Colombia, by registering our product and getting regular supplies